CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$2.95
-0.03 (-1.01%)
Open$3.02
Previous Close$2.98
Day High$3.13
Day Low$2.93
52W High$6.16
52W Low$1.96
Volume—
Avg Volume2.01M
Market Cap336.44M
P/E Ratio—
EPS$-1.40
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+566.8% upside
Current
$2.95
$2.95
Target
$19.67
$19.67
$12.33
$19.67 avg
$23.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.37M | 2.18M | 70.28M |
| Net Income | -159,333,941 | -227,945,552 | -10,926,196 |
| Profit Margin | -11,665.3% | -11,082.0% | -15.6% |
| EBITDA | -170,442,040 | -257,383,465 | -18,107,687 |
| Free Cash Flow | — | — | -6,087,830 |
| Rev Growth | -37.1% | -37.1% | +8.8% |
| Debt/Equity | 0.01 | 0.01 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |